Topic: What More We can do on Hepatitis C?

Hepatitis C virus (HCV) is an enveloped virus with a 9.6 kb single stranded RNA genome. Six HCV genotypes and a large number of subtypes have been identified. HCV is an important world-wide health and economic problem through direct and indirect medical cost associated with managing liver disease, and decreased work productivity. A hundred and eighty million people are infected with HCV in the world. It is the cause of acute hepatitis, chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Besides that, it may result in extra-hepatic manifestations such as mixed cryoglobulinemia, chronic kidney disease, porphyria cutaneatarda, and type 2 diabetes mellitus, rheumatoid-like nondestructive inflammatory arthritis and depression. HCV is associated with the increasing liver-related mortality.
HCV is one of the important factors (20 % of all causes) for developing HCC. Almost 700,000 persons died from HCC in a year. HCC is the 6th most common cancer but the third most common cause of death from the cancer.
Those are the reasons why we made a plan to establish a Special Issue about "What More Can We Do on Hepatitis C?". It is hoped that this Special Issue will bring novel insights and new solutions to the liver cancer research field.

30 Apr 2018